Our pipeline

Targeting the source of the immune response.

We are developing lymph-node–targeted immunotherapies for severe food allergies, with the goal of creating durable immune tolerance through a short course of treatment.

Explore our pipeline ↓
The need for new treatments
33 millionAmericans

Food allergy touches
millions of lives.

Approximately 33 million people in the United States live with at least one food allergy. The impact reaches beyond meals, shaping everyday choices for patients and families.

Source: Food Allergy Research & Education (FARE) ↗
Indication strategy

One approach.
Multiple food allergies.

IndicationCause & prevalencePortfolio priority

Alpha-gal syndrome

Cause: A tick-bite–associated allergy to alpha-gal, a sugar found in mammalian meat and other products. In the U.S., it is most often linked to lone star tick bites.
U.S. burden: As many as 450,000 people may be affected; the true prevalence is unknown. Source: CDC.

Priority indication

Shellfish allergy

Cause: An allergic immune response to proteins found in crustaceans and mollusks.
U.S. adult prevalence: An estimated 2.9%, based on a national survey published in 2019. Source: 2019 study.

Priority indication

Peanut allergy

Cause: An allergic immune response to proteins in peanuts.
U.S. adult prevalence: An estimated 1.8%, based on a national survey published in 2019. Source: 2019 study.

Planned expansion

Indication priorities are shown, not clinical development stages. All programs are investigational.

Our therapeutic goal

Retraining the immune
system at its source.

Our goal is to develop a targeted treatment that addresses the underlying allergic immune response.

Lymph nodes are key sites of immune education. Our intralymphatic immunotherapy approach is designed to deliver treatment directly to these sites, with the aim of changing how the immune system responds to a food allergen.

Targeted delivery

Deliver treatment to the lymph node, where immune cells coordinate their response.

Immune retraining

Seek to shift the response to a food allergen toward tolerance through targeted immune education.

Lasting benefit

Aim for durable immune tolerance following a short course of treatment.

These are development goals. Safety, efficacy, and durability in food allergy have not been established.

Advancing a new approach to severe food allergy. Connect with Auni ↗